|
Crystal Mackall |
Stanford University |
Phase 1 |
Recruiting |
57 |
|
|
Thomas Kipps |
University of California, San Diego |
Phase 1/2 |
Recruiting |
156 |
|
|
Thomas Kipps |
University of California, San Diego |
Phase 1 |
Active, not recruiting |
29 |
|
|
Irving Weissman |
Stanford University |
Phase 1 |
Completed |
88 |
|
|
Michael Pulsipher |
Children's Hospital of Los Angeles |
Phase 1/2 |
Launching |
N/A |
|
|
Edward Kavalerchik |
Angiocrine Bioscience, Inc. |
Phase 1 |
Launching |
N/A |
|
|
Paul Finnegan |
Angiocrine Bioscience, Inc. |
Phase 1 |
Launching |
N/A |
|
|
Mehrdad Abedi |
University of California, Davis |
Phase 1/2 |
Recruiting |
18 |
|
- Leukemia, Acute Myeloid (AML)
|
Colleen Delaney |
Nohla Therapeutics Inc |
Phase 2 |
Active, not recruiting |
146 |
|
- Leukemia, Acute Myeloid (AML)
|
Mark Chao |
Forty Seven Inc. |
Phase 1 |
Recruiting |
96 |
|
|
Matthew Spear |
Poseida Therapeutics, Inc. |
Phase 1 |
Recruiting |
40 |
|